Article
Immunology
Mou Peng
Summary: This study aimed to classify immune subtypes and investigate the tumor microenvironment of urothelial carcinoma to improve the understanding and response of immunotherapy. Patients were classified into four immune subtypes with different molecular expression, immune cell infiltration, and clinical characteristics. The C3 immune subtype displayed abundant immune cell infiltrations and hot tumor phenotypes, while the C4 immune subtype had few immune cell infiltrations and cold tumor phenotypes. C3 subtype showed higher expression of tumor mutation burden, inhibitory immune checkpoints, and immunogenic cell death modulators. Patients with the C4 subtype had a better overall survival probability. TGFB3 was identified as a potential biomarker for predicting immunotherapy resistance. This study provides a bioinformatics basis for understanding the immune landscape of urothelial carcinoma.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ryutaro Shimizu, Masashi Honda, Shogo Teraoka, Tetsuya Yumioka, Noriya Yamaguchi, Bunya Kawamoto, Hideto Iwamoto, Shuichi Morizane, Katsuya Hikita, Atsushi Takenaka
Summary: This study aimed to investigate the association between sarcopenia at the time of chemotherapy induction and prognosis in patients with urothelial carcinoma. The results showed that paraspinal muscle index measurements obtained during chemotherapy induction were independent prognostic factors. Absence of sarcopenia may lead to long-term survival in urothelial carcinoma patients undergoing chemotherapy.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemical Research Methods
Chao-Jung Chen, Che-Yi Chou, Kuo-Hsiung Shu, Hung-Chun Chen, Ming-Cheng Wang, Chia-Chu Chang, Bang-Gee Hsu, Mai-Szu Wu, Yuan-Lung Yang, Wen-Ling Liao, Chieh Yang, Yu-Tien Hsiao, Chiu-Ching Huang
Summary: This study identified BRDT, CYBP, GARS, and HDGF as novel urinary UC biomarkers with high discrimination ability. These markers showed better diagnostic values compared to other reported UC markers, and a panel including BRDT, HDGF, GARS, and CYFR21.1 had high AUC values for discriminating between UC and normal or control groups.
JOURNAL OF PROTEOME RESEARCH
(2021)
Article
Oncology
Gorka Larrinaga, Julio Calvete-Candenas, Jon Danel Solano-Iturri, Ana M. Martin, Angel Pueyo, Caroline E. Nunes-Xavier, Rafael Pulido, Juan F. Dorado, Jose I. Lopez, Javier C. Angulo
Summary: This study provides a novel description of the (Pro)renin receptor (PRR) protein and its prognostic role in invasive urothelial cancer of the bladder. It demonstrates that PRR expression is an independent prognostic marker and may be a potential target in urothelial carcinoma. The study suggests that PRR activates pathogenic pathways contributing to cell proliferation, immunosuppressive microenvironments, and aggressive neoplastic phenotypes.
Article
Oncology
Minami Une, Masaya Ito, Hiroaki Suzuki, Masahiro Toide, Shuichiro Kobayashi, Hiroshi Fukushima, Fumitaka Koga
Summary: In this study, the mutual relationship between the controlling nutritional status (CONUT) score and sarcopenia as prognostic factors in patients with advanced urothelial carcinoma (aUC) was comprehensively examined. The study found that the CONUT score and sarcopenia were significant and independent prognostic biomarkers and incorporating them into established prognostic models increased their predictive accuracy. These objective indices of a patient's general condition may assist in treatment decision-making for patients with aUC.
Article
Veterinary Sciences
Veronica Mollica Govoni, Claudio Pigoli, Eleonora Brambilla, Felipe Augusto Ruiz Sueiro, Rafael Torres Neto, Renee Laufer-Amorim, Juliany Gomes Quitzan, Valeria Grieco, Carlos Eduardo Fonseca-Alves
Summary: This study evaluated Caveolin-1, GATA-3, and Ki67 immunostaining in canine bladder urothelial carcinoma (UC) samples and found that Caveolin-1 and GATA-3 expression could be promising markers for bladder UC aggressiveness.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Oncology
Se-Il Go, Mi Jung Park, Gyeong-Won Lee
Summary: A low CXI is associated with poor prognosis, treatment intolerance, low treatment response rate, in patients with SCLC.
Review
Oncology
Sarah E. Fenton, David J. VanderWeele
Summary: The use of ADCs in urothelial carcinoma is expanding, with approved medications and ongoing studies. Biomarkers for treatment response prediction are not commonly used in clinical trials and practice. This review summarizes the knowledge on potential predictive biomarkers for ADCs in UC and discusses areas where biomarkers may improve patient care.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Christoph Pickl, Simon Engelmann, Florian Girtner, Miodrag Guzvic, Bas W. G. van Rhijn, Valerie Hartmann, Sonja Holbach, Sebastian Kaelble, Maximilian Haas, Bernd Rosenhammer, Johannes Breyer, Maximilian Burger, Roman Mayr
Summary: Urothelial carcinoma is an aggressive cancer. In addition to therapeutic strategies, research into risk and prognostic factors is important. This study assessed specific parameters of body composition and found that loss of skeletal muscle mass is a significant risk factor, while visceral fat seems to be protective. These findings suggest that body composition can be used for risk stratification.
Article
Mathematical & Computational Biology
Peiyuan Li, Gangjie Qiao, Jian Lu, Wenbin Ji, Chao Gao, Feng Qi
Summary: PVT1 plays a crucial role in the progression and prognosis of bladder urothelial carcinoma (BLCA), with high expression associated with lower survival rates. It serves as an independent prognostic factor and can be used as a medium biomarker to predict survival after cystectomy.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2022)
Article
Immunology
Mulin Liu, Siyi Chen, Aihui Zhang, Qin Zheng, Juan Fu
Summary: The study indicated that elevated PLAUR expression in BLCA is associated with lower survival rates and immune infiltration. This suggests that PLAUR could potentially serve as a valuable biomarker or immunotherapeutic target for BLCA.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Oncology
Benjamin N. Schmeusser, Henry Biermann, Edouard H. Nicaise, Adil A. Ali, Dattatraya H. Patil, Eric Midenberg, Talia Helman, Manuel Armas-Phan, Reza Nabavizadeh, Shreyas S. Joshi, Vikram M. Narayan, Mehmet A. Bilen, Sarah P. Psutka, Kenneth Ogan, Viraj A. Master
Summary: This study evaluates the association between low creatinine to cystatin-C ratio (Cr/Cys-C) and overall survival (OS) and recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) treated with nephrectomy. The results suggest that low Cr/Cys-C is associated with inferior oncologic outcomes and may serve as a serum biomarker for the presence of sarcopenia in this patient population.
Article
Oncology
Thomas van Doeveren, Jose A. Nakauma-Gonzalez, Andrew S. Mason, Geert J. L. H. van Leenders, Tahlita C. M. Zuiverloon, Ellen C. Zwarthoff, Isabelle C. Meijssen, Angelique C. van der Made, Antoine G. van Der Heijden, Kees Hendricksen, Bas W. G. van Rhijn, Charlotte S. Voskuilen, Job van Riet, Winand N. M. Dinjens, Hendrikus J. Dubbink, Harmen J. G. van de Werken, Joost L. Boormans
Summary: By sequencing genes in 15 UTUC patients treated by RNU, it was found that the majority of patients had a clonal relationship between UTUC and subsequent UCB, supporting the idea that UCBs following UTUC surgery are primarily clonally derived recurrences.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Geriatrics & Gerontology
Timo E. Strandberg, Susan L. Levinson, Mark J. DiNubile, Satu Jyvakorpi, Mika Kivimaki
Summary: This study found that plasma gelsolin (pGSN) concentration is associated with the frailty phenotype and can predict mortality in frail individuals. In a cohort of older males with high socioeconomic status, higher baseline pGSN concentration is associated with a lower mortality rate.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Urology & Nephrology
Mathieu Rouanne, Camelia Radulescu, Julien Adam, Yves Allory
Summary: This review critically evaluated the role of PD-L1 as a predictive biomarker for response to immune checkpoint blockade in patients with urothelial bladder carcinoma, discussing its limitations in clinical practice. Evidence data regarding PD-L1 as a predictive biomarker were detailed, including companion diagnostic assays and scoring methods. Use of PD-(L)1 monoclonal antibodies are restricted to patients with PD-L1 positive status in certain clinical settings, while identification of biomarkers with high negative predictive value is crucial for non-responders.
WORLD JOURNAL OF UROLOGY
(2021)
Article
Oncology
Shumpei Yamamoto, Hiroshi Fukushima, Shohei Fukuda, Sho Uehara, Yosuke Yasuda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Yasuhisa Fujii
Summary: This study found that early cancer cachexia phenotypes were significantly associated with the survival of aUC patients receiving pembrolizumab, with the MFW group showing the worst prognosis and the NW and FW groups having a higher likelihood of long-term survival.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Ryuhei Okada, Takuya Kato, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Daiki Fujimura, Shuhei Okuyama, Hideyuki Furumoto, Hiroshi Fukushima, Peter L. Choyke, Hisataka Kobayashi
Summary: This study compared the effects of Panitumumab and Cetuximab in APCs for NIR-PIT and the impact of different light exposure regimens on tumor growth in an immunocompetent mouse model. The results showed that APCs with longer half-life and double light exposure had superior outcomes in cancer cell-targeted NIR-PIT.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yoh Matsuoka, Sho Uehara, Kazuma Toda, Hiroshi Fukushima, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Ryoichi Yoshimura, Kazunori Kihara, Yasuhisa Fujii
Summary: In low- to intermediate-risk prostate cancer, focal brachytherapy (FB) patients achieved better genitourinary function compared to pair-matched radical prostatectomy (RP) patients, and there were no significant differences in salvage therapy needed between the two treatment cohorts.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer treatment that combines antibody-photoabsorber-conjugate (AbPC) and NIR light. It is effective for surface-located skin cancers such as melanoma. The study found that CD29-targeted NIR-PIT showed better tumor growth inhibition and when combined with anti-CTLA4 checkpoint inhibitor, it resulted in improved immune response and prolonged survival.
Article
Oncology
Hiroaki Wakiyama, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: The study evaluates the anti-tumor efficacy of VISTA-targeted NIR-PIT in murine tumor models. Results show that VISTA-targeted NIR-PIT enhances anti-tumor immune responses by depleting immune suppressor cells, inhibits tumor progression, and prolongs survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Hiroshi Fukushima, Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Eisaku Kondo, Peter L. Choyke, Hisataka Kobayashi
Summary: This study investigates the therapeutic efficacy of ICAM-1 targeted NIR-PIT in TNBC and demonstrates that this treatment method effectively damages cancer cells and inhibits tumor growth, suggesting its potential clinical application in TNBC treatment.
Article
Chemistry, Multidisciplinary
Hiroshi Fukushima, Siddharth S. Matikonda, Syed Muhammad Usama, Aki Furusawa, Takuya Kato, Lenka Stackova, Petr Klan, Hisataka Kobayashi, Martin J. Schnermann
Summary: Photoconvertible tracking strategies, such as PACT, are used to evaluate the migration of immune cells into tumor-draining lymphatics. PACT utilizes a recently discovered cyanine photoconversion reaction and near-infrared wavelengths, eliminating the need for genetic engineering. This approach provides a straightforward and quantitative method for studying cell migration dynamics.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Article
Medicine, Research & Experimental
Takuya Kato, Ryuhei Okada, Aki Furusawa, Hiroaki Wakiyama, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment modality that selectively kills target cells using antibody-photoabsorber conjugates (APCs) and NIR light. This study compared the efficacy of anti-CTLA4-F(ab')(2) and anti-CTLA4-IgG for NIR-PIT, and found that anti-CTLA4-IgG was more effective in reducing tumor growth and activating CD8(+) T cells.
MOLECULAR PHARMACEUTICS
(2022)
Article
Oncology
Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that utilizes an antibody-IRDye700DX (IR700) conjugate and NIR light to induce cell membrane damage and cell death. PDPN-targeted NIR-PIT showed efficacy in destroying cancer cells and cancer-associated fibroblasts (CAFs), suppressing tumor progression, and enhancing host antitumor immunity.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Urology & Nephrology
Yuki Nakamura, Hiroshi Fukushima, Kasumi Yoshitomi, Takahiko Soma, Masaki Kobayashi, Bo Fan, Motohiro Fujiwara, Yudai Ishikawa, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Yasuhisa Fujii
Summary: This study assessed the prognostic significance of the detailed bladder neck involvement (BNI) location in non-muscle-invasive bladder cancer (NMIBC) patients. Dorsal bladder neck involvement was found to be an independent risk factor for progression in primary NMIBC. A simple and practical prognostic model, including the BNI location, was developed to assist in selecting the optimal treatment and timing.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Yoshitomo Yamaguchi, Hajime Tanaka, Koichiro Kimura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Soichiro Yoshida, Minato Yokoyama, Akihiro Hirakawa, Ukihide Tateishi, Steven C. Campbell, Yasuhisa Fujii
Summary: This study investigated the prognostic impact of radiological infiltrative feature (r-IF) of primary renal tumors in metastatic renal cell carcinoma (mRCC). The findings suggest that r-IF is strongly associated with poor cancer-specific survival (CSS) in mRCC patients. Combining r-IF with the International Metastatic RCC Database Consortium (IMDC) risk model may improve prognostic accuracy.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Nutrition & Dietetics
Shugo Yajima, Hiroshi Fukushima, Shioto Oda, Rikuto Yasujima, Kohei Hirose, Naoya Okubo, Yosuke Umino, Madoka Kataoka, Yasukazu Nakanishi, Fumitaka Koga, Hitoshi Masuda
Summary: This study aimed to investigate the role of the SARC-F questionnaire as a screening tool for elderly patients undergoing elective major surgery for urologic cancer and to evaluate its correlation with indicators of sarcopenia. The study found that SARC-F scores were associated with postoperative ambulation failure and overall survival, suggesting that it can be used to identify elderly patients at a higher risk of unfavorable outcomes after surgery.
CLINICAL NUTRITION
(2023)
Article
Oncology
Fumitaka Koga
Summary: This article reviews the use of selective bladder-sparing therapy for muscle-invasive bladder cancer and compares its oncological outcomes with radical cystectomy. It also discusses predictive biomarkers for treatment decision-making and a novel strategy to boost the immune response in bladder-sparing therapy.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Urology & Nephrology
Ichiro Yonese, Masaya Ito, Yuma Waseda, Shuichiro Kobayashi, Masahiro Toide, Ryoji Takazawa, Fumitaka Koga
Summary: This study aimed to investigate whether even a minimally invasive diagnostic procedure like ureteral catheterization (UCath) could significantly increase the risk of intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). A retrospective study enrolled 163 patients undergoing RNU for UTUC between 2010 and 2021. The results showed that UCath was significantly associated with IVR and shorter IVR-free survival (IVRFS) in UTUC patients.
WORLD JOURNAL OF UROLOGY
(2023)
